The FDA Approved a New Flu Treatment, Just In Time for Flu Season

The Food and Drug Administration (FDA) has approved a new antiviral influenza treatment. The agency on Wednesday approved Genentech’s drug Xofluza, which can be taken via a single oral dose to help patients recover more quickly from the flu. It’s the “first new antiviral flu treatment with a novel mechanism of action approved by the FDA in nearly 20 years,” FDA Commissioner Dr. Scott Gottlieb said in a statement. The main factor differentiating Xofluza from other antiviral flu treatments on the market, such as Tamiflu and Relenza, is the way it’s taken. Xofluza is the only antiviral that can be taken as a single oral dose. Tamiflu, for example, must be taken orally twice daily for five days, while Relenza is an inhaled powder. In clinical trials, patients who took Xofluza got over their flu symptoms faster than those who took a placebo pill, though the drug did not alleviate symptoms significantly faster than other flu treatments. A representative from Genentech told TIME that the drug, which was approved for people older than 12 who have showed symptoms of uncomplicated influenza for 48 hours or less, will be available across the U.S. “in the coming weeks.” Its wholesale cost will be $150, though insured patients who use a coupon may purchase it for as little as $30, the company said. While antivirals offer valuable benefits to those who have already contracted influenza, Gottlieb stressed in the statement that the medications are ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Drugs healthytime onetime Source Type: news

Related Links:

Abstract In January 2020, the subclade 2.3.4.4h of highly pathogenic avian influenza (H5N6) virus infected migratory whooper swans and mute swans in Xinjiang, western China. The virus is lethal to chickens and ducks but has low pathogenicity in mice. Antigenically, this subclade is similar to the H5N1 vaccine seed virus Re-11. PMID: 33030424 [PubMed - as supplied by publisher]
Source: Emerging Infectious Diseases - Category: Infectious Diseases Authors: Tags: Emerg Infect Dis Source Type: research
Flu season could be like no other this year and a national campaign to promote the flu vaccine is urgent, say scientistsA national public health campaign promoting the flu vaccine is urgently needed to avoid stretched healthcare services being overwhelmed this winter as the US faces cold season while still struggling to gain control of the coronavirus pandemic, scientists have warned.Influenza or seasonal flu is a perennial public health burden that, like Covid-19, causes most severe problems among elderly people and those with underlying health conditions.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Flu Coronavirus outbreak US news Science Infectious diseases Source Type: news
In this study, we further evaluated the broad-spectrum antiviral activity of the ten identified compounds by testing their activity against ZIKV. Among the ten compounds, Azaribine (SI-MTT = 146.29), AVN-944 (SI-MTT = 278.16), and Brequinar (SI-MTT = 157.42) showed potent anti-ZIKV activity in post-treatment therapeutic conditions. We also observed potent anti-ZIKV activity for Mycophenolate mofetil (SI-MTT = 20.51), Mycophenolic acid (SI-MTT = 36.33), and AVN-944 (SI-MTT = 24.51) in pre-treatment prophylactic conditions and potent co-treatment inhibitory activity for Obatoclax (SI-MTT = 60.58), Azaribine (SI-MTT = 91.51),...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p4").init({"mcp":"cbs","width":"100%","height":"100%","video":"4709972","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p4","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Syndicated CBSN Boston Coronavirus Source Type: news
In this Viewpoint, CDC scientists discuss the public health urgency of increasing influenza vaccination uptake early in the 2020-2021 season to ameliorate the threat to patients and hospitals of overlapping outbreaks, and urges clinicians to strongly recommend the vaccine and administer it to patients whenever and wherever possible.
Source: JAMA - Category: General Medicine Source Type: research
ns JA Abstract COVID-19 has been disturbing human society with an intensity never seen since the Influenza epidemic (Spanish flu). COVID-19 and Influenza are both respiratory viruses and, in this study, we explore the relations of COVID-19 and Influenza with atmospheric variables and socio-economic conditions for tropical and subtropical climates in Brazil. Atmospheric variables, mobility, socio-economic conditions and population information were analyzed using a generalized additive model for daily COVID-19 cases from March 1st to May 15th, 2020, and for daily Influenza hospitalizations (2017-2019) in Brazilian s...
Source: Environmental Research - Category: Environmental Health Authors: Tags: Environ Res Source Type: research
This article is republished from The Conversation under a Creative Commons license. Read the original article. The post Why COVID-19 Vaccines Need to Prioritize ‘Superspreaders’ appeared first on Inter Press Service.
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Global Headlines Health COVID-19 Source Type: news
NEW YORK, September 8, 2020 — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson &Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines. All nine CEOs signed the following pledge: We, the und...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
France counts more than 7,000 new infections for second day; US public health officials prepare for October vaccine rollout; Robert Pattinson tests positive for Covid-19. Follow the latest updatesFrench PM says jobs and green economy at heart of recovery planIndia logs record 83,883 Covid-19 cases in dayGSK and Sanofi to start human trials of potential Covid-19 vaccineSee all our coronavirus coverage4.43amBSTAustralian Prime Minister Scott Morrison says that that the country plans to introduce a “hotspot” approach to tourism from New Zealand, which will allow people from parts of New Zealand that are declared s...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus outbreak World news US news UK news Australia news Science Infectious diseases Source Type: news
Homœopathic Links DOI: 10.1055/s-0040-1715865The current outbreak of novel corona virus that began in China, created massive disaster worldwide resulting in thousands of deaths and enormous impact on health system &economic. This viral infection facilitates damage of alveolar macrophages and epithelial cells of lung caused by cytokine storm and deregulated immune responses and transmitted rapidly through the droplet infection via cough, sneeze and through contact reporting spectrum from asymptomatic cases to symptomatic manifestations which include. The fever, cough and ranges shortness of breath with high-risk p...
Source: Homoeopathic Links - Category: Complementary Medicine Authors: Tags: Review Article Source Type: research
More News: Centers for Disease Control and Prevention (CDC) | Clinical Trials | Food and Drug Administration (FDA) | Health | Influenza | Influenza Vaccine | Insurance | Oseltamivir | Outbreaks | Relenza | Tamiflu | Vaccines | Zanamivir